The global allergy diagnostics and therapeutics market size was estimated at USD 29.36 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% from 2023 to 2030. Some of the major factors driving the market growth are the rising prevalence of allergy disorders in children & geriatric population, increasing adoption of IVD techniques, and improving access to diagnostic tools in developing countries of the Asia Pacific region.
Furthermore, factors such as changing lifestyles, growing pollution, unhealthy habits such as smoking, and urbanization are contributing to the increasing incidence of allergic conditions. The introduction of therapeutically advanced drugs such as immunotherapy, which can solve unmet patient needs, is expected to boost market growth over the forecast period. The increasing incidence of allergies is one of the key factors contributing to the growth of the allergy therapeutics market over the forecast period.
Rising exposure to outdoor and indoor air pollutants and occupational exposure are among the high-risk factors causing chronic respiratory diseases. The prevalence of allergies is much higher in the urban population than in the rural population due to rising exposure to environmental pollutants due to industrial activities and urbanization.
As per Mayo Clinic, food allergies affect about 8% of children under the age of 5 and up to 4% of adults. Similarly, as per data from the Asthma and Allergy Foundation of America, in 2021, in the U.S., about 81 million people were diagnosed with seasonal allergic rhinitis, representing around 26% affected adults and 19% affected children.
The development of low-cost and effective in vitro diagnostic tests for allergy determination, rising lab automation, and an increase in reagent rental agreements are some of the factors expected to contribute to the market growth for allergy diagnostics and therapeutics in the coming years. Various studies are being conducted, which include biosensors combined with nanoparticles for the determination of allergenic compounds. Out of all, gold nanoparticles are majorly used due to the ease of their synthesis.
Manufacturers are now focusing on remodeling their drug development processes to cater to patient needs across the globe. For instance, in September 2020, Dr. Reddy’s announced the launch of its OTC eye allergy drop called Olopatadine Hydrochloride Ophthalmic Solution.
Adverse effects, such as drowsiness, blurred vision, insomnia, & loss of appetite caused by conventional therapies are driving clinical urgency to initiate the development of a new generation of drugs. High R&D investment made by these companies is anticipated to result in the large-scale development of new drug candidates.
For instance, in November 2021, Angany and Lincoln Diagnostics collaborated on Angany's approach to allergists in the U.S. Angany presents an innovative approach to allergy immunotherapy that is based on integrative science and is intended to surmount the limitations of the current desensitization methods.
The consumables segment accounted for the largest revenue share of over 62.89% of the allergy diagnostics market in 2022 and is anticipated to expand at a significant CAGR during the forecast period, due to its indispensable applications in diagnostic tests. The associated benefits such as availability of kits specific to each allergen and ease of access are expected to fuel segment growth in the coming years.For instance, allergen microarray kits, which have become more sensitive and provide individualized patient assessment & monitoring, are expected to propel the industry even further.
Instruments held the second largest share in the allergy diagnostics market in 2022, owing to the introduction of technologically advanced products, which offer better results and high throughputs. An increase in lab automation and improvements in the healthcare sector is expected to serve this market with lucrative growth opportunities.
The increasing focus on R&D activities by companies to develop novel diagnostic equipment, tests, or kits to address high unmet medical needs has a major impact on market development. Omega Diagnostics, for example, received clearance from the China National Medical Products Administration (NMPA) for a food detective test in China in November 2020.
Inhaled allergies accounted for the largest revenue share of over 49.58% in 2022 in the allergy diagnostics and therapeutics market, owing to the growing incidences of respiratory allergies caused by rising air pollution and industrialization. According to estimates published by the Allergy and Asthma Foundation of America, seasonal allergic rhinitis was to affect approximately 81 million individuals in the U.S. by 2021. This corresponds to approximately 26% (67 million) of adults & 19% (14 million) of minors, and this number is expected to rise over the forecast period.
Hence, the increasing incidence of allergic rhinitis is expected to present this market with future growth opportunities. The drug allergies segment is expected to progress at the fastest CAGR over the foreseeable future. Drug allergies may lead to Steven-Johnson syndrome and toxic epidermal necrolysis in children. Chemotherapy drugs, antiepileptic drugs, and sulfonamide drugs are the most common agents of drug allergies.
These allergens lead to various diseases such as contact dermatitis, which is skin inflammation. The segment is expected to showcase positive growth in the coming years due to the increasing availability of treatment options and growing awareness about drug allergies among patients.
The in vivo test segment accounted for a share of 48.85% in the market for allergy diagnostics and therapeutics in 2022. This is attributed to the increasing adoption of several in vivo tests due to their convenient, cost-effective, and safe & reliable properties as compared to other types. The growing demand for efficient, rapid, and simple testing options has fueled the growth of in vivo diagnostic tests. These tests look at the reactivity and susceptibility of dermal mast cells, which can indicate allergic sensitivity. To ensure reliability, these procedures include skin exams with standardized allergenic extracts.
The in vitro tests segment is estimated to expand at a significant CAGR over the forecast period. This test is utilized for identifying allergen-specific immunoglobulin E. (IgE). A radioallergosorbent screening is an in vitro method for identifying allergen-specific antibodies of a new immunoglobulin class known as IgND. The increasing prevalence of various allergic diseases among the population raises the demand for early detection & diagnosis of allergens, which is expected to drive the need for efficient diagnostic tests or systems, propelling the market growth.
Antihistamines contributed significantly to the overall allergy therapeutics market with over 18.05% share as of 2022, due to their non-sedating properties and wide application in treating allergic conditions. Various organizations are highlighting the use of antihistamines for the treatment of various allergic conditions. For instance, Allergy UK, a leading national charitable organization dedicated to supporting patients with allergies, stated that antihistamines are considered one of the best readily available antiallergic medications.
On the other hand, immunotherapy is expected to be the fastest-growing segment in the allergy therapeutics market during the forecast period due to an increase in demand for sublingual vaccines, an extensive drug pipeline, and ongoing clinical trials on monoclonal antibodies for the treatment of allergic disorders.A shift in preference from the use of conventional treatments to immunotherapy is further anticipated to boost the allergy therapeutics market in the coming years.
The North America allergy diagnostics and therapeutics market led with a revenue share of 36.36% in 2022, owing to factors such as the rising incidences of allergy and favorable government initiatives in the region. North America is a developed region with high healthcare expenditure. According to data from the Asthma and Allergy Foundation of America, the cost of nasal allergy ranges between USD 3-4 billion annually.
The presence of regulatory bodies in North American countries is expected to fuel the advancement of drugs in the near future. This is primarily because these bodies play a fundamental role in creating awareness among consumers, regarding the potential of early diagnosis and therapeutics of allergies.
Asia Pacific is projected to exhibit the fastest CAGR over the forecast period. Asia Pacific, with Japan, China, and India being notable markets, is projected to boost the regional market. Key players in these countries are undertaking various strategic initiatives to increase their dominance. For instance, in October 2022, Siemens Healthineers divided Asia Pacific into two regions (China and the rest of Asia Pacific) to achieve its full potential in the region. Moreover, in May 2021, Glenmark launched its nasal spray Ryaltris, which can be used to treat moderate to severe allergic rhinitis, in India.
The allergy diagnostics & therapeutics industry is highly competitive, and market players are involved in activities such as strategic collaborations, new product launches, acquisitions, technological advancements, and regional expansions. For instance, in August 2022,Thermo Fisher Scientific's ImmunoCAP blood tests for identifying wheat & sesame allergies were approved by the FDA. According to the company, in vitro diagnostic tests, which detect specific antibodies, can differentiate between wheat sensitization & grass cross-reactivity and help many patients avoid unnecessary dietary restrictions. Some prominent players in the global allergy diagnostics and therapeutics market include:
EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.)
DASIT Group SPA
Thermo Fisher Scientific, Inc.
Minaris Medical America, Inc.
Siemens Healthcare GmbH
Omega Diagnostics Group PLC
Lincoln Diagnostics, Inc.
HOB Biotech Group Corp., Ltd.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Astellas Pharma Inc.
Market size value in 2023
USD 31.34 billion
Revenue forecast in 2030
USD 48.86 billion
CAGR of 6.6% from 2023 to 2030
Base year for estimation
2018 – 2021
2023 – 2030
Revenue in USD million/billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Allergen type, test type, drug class, product, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
R-Biopharm AG; EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.); DASIT Group SPA; AESKU.GROUP GmbH; bioMérieux; Thermo Fisher Scientific, Inc.; Stallergenes Greer; Minaris Medical America, Inc.; Siemens Healthcare GmbH; Omega Diagnostics Group PLC; HYCOR Biomedical; Lincoln Diagnostics, Inc.; Alcon; HOB Biotech Group Corp, Ltd.; Danaher; AbbVie, Inc.; Allergy Therapeutics; Sanofi; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd; GSK plc; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Astellas Pharma Inc.
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global allergy diagnostics and therapeutics market report based on product, allergen type, test type, drug class, and region:
Product Outlook (Revenue, USD Billion, 2018 - 2030)
Allergen Type Outlook (Revenue, USD Billion, 2018 - 2030)
Other Food Allergens
Test Type Outlook (Revenue, USD Billion, 2018 - 2030)
In vivo Test
Skin Prick Test
In vitro Test
Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
Mast Cell Stabilizers
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
Middle East and Africa (MEA)
b. The global allergy diagnostics and therapeutics market size was estimated at USD 29.36 billion in 2022 and is expected to reach USD 31.34 billion in 2023.
b. The global allergy diagnostics and therapeutics market is expected to grow at a compound annual growth rate of 6.6% from 2023 to 2030 to reach USD 48.86 billion by 2030.
b. North America dominated the allergy diagnostics and therapeutics market with a share of 36.36% in 2022. This is attributable to high incidence of respiratory allergic disorders along with rising awareness levels about allergy diagnostics and adoption of in vitro blood tests.
b. Some key players operating in the allergy diagnostics and therapeutics market include bioMerieux, Thermo Fisher Scientific, Danaher Corporation, Omega Diagnostics, Hitachi Chemical Diagnostics, Stallergenes Greer, Siemens Healthcare, Lincoln Diagnostics, Hycor Biomedical, HOB Biotech Group, and Alcon Laboratories.
b. Key factors driving the allergy diagnostics and therapeutics market growth include increasing incidences of allergy diseases; increasing demand for IVD tests for allergy diagnosis; and growing healthcare expenditure triggering development of effective allergy diagnostic & therapeutic products.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.